Navigation Links
Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
Date:6/5/2008

BERKELEY HEIGHTS, N.J., June 5 /PRNewswire-FirstCall/ --Genta Incorporated (OTC Bulletin Board: GNTA) announced today that the Company has entered into definitive agreements with institutional and accredited investors to place Senior Secured Convertible Notes due 2010 totaling in aggregate up to $40 million in gross proceeds before fees and expenses. The closing of the first $20 million of Notes is expected to take place on or about June 6, 2008, subject to the satisfaction of customary closing conditions.

The Notes will bear interest at an annual rate of 15% payable at quarterly intervals in stock or cash at the Company's option, and will be convertible into shares of Genta common stock at a conversion rate of 100,000 shares of common stock for every $1,000.00 of principal. The first one-half of the Notes, or $20 million, will be issued upon initial closing of the transaction. Holders of the Notes shall have the right, but not the obligation, for the following 12 months following the initial closing date to purchase in whole or in part up to an additional $20 million of the Notes. The Company shall have the right to force conversion of the Notes in whole or in part if the closing bid price of the Company's common stock exceeds $0.50 for a period of 20 consecutive trading days. Certain members of senior management of Genta Incorporated participated in this offering. The Notes are secured by a first lien on all assets of Genta. The Notes include certain events of default, including a requirement that the Company obtain stockholder approval within a specified period of time to amend its certificate of incorporation to authorize additional shares of common stock.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq:

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
2. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
3. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
4. Dr. Elizabeth Brown Joins Argenta TEC
5. Syngenta To Build Major Global Biotech Research Center in Beijing, China
6. Genta Restructures Operations to Focus on Priority Initiatives
7. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
8. Auditors for Genta Incorporated Express Going Concern Qualification
9. Genta Announces Senior Management Changes
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Incorporated to Present at the BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ ...search report is available in its catalogue: ,,...to 2013 ,, http://www.reportlinker.com/p01655...-to-2013.html ,, Brazil Bioethanol Market Anal...he report provides detailed analysis and forecasts...
(Date:11/24/2009)..., The New York investment...Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible...investor. The private placement was arranged by KT...d advisor. , New York (PR... investment bank KTA Capital, LLC ("KTA Capit...
(Date:11/24/2009)..., Health care employment...mains the only one to show consistent growth durin...ty hospitals remain in trouble, and health systems...al personnel, instead of just administrators. , ...- Health care employment continued growing in Octo...
(Date:11/24/2009)..., , SEATTLE, Nov. 24 Blue...any and the Odessa Public Development Authority (O...n State,s Community Economic Revitalization Board ...t the state,s first specialty biochemical biorefin...t will significantly speed the development of our ...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
... CVM ), will present today at the Noble Financial ...On August 20, 2007 at 3:30 pm E.D.T. Geert Kersten...resentation regarding CEL-SCI,s late stage,cancer ...te in a question,and answer session following the ...e day. The presentation with streaming video and ...
...Poised for Market Launch, KIRKLAND, Wash., Aug. 2...eloping innovative devices for the treatment of ar...a VP of Sales, Joseph W.,Rafferty, and has started...troduction of its first product, Pathway PV(TM) At... old 10,000-square-foot facility to a,new state-of...
... Board: GOVX), an Atlanta-based biotechnology comp... results and provided an,operational update for th...for the Quarter Ended June 30, 2007 The Company r...ths,ended June 30, 2007, compared to net income of... months ended June 30, 2007, the Company,s net los...
Other Biology Technology:CEL-SCI to Present at the Noble Financial Conference 2Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 6
(Date:11/26/2009)...resistant Staphylococcus Aureus ) and other drug-...temperature plasma prototype devices have been dev...ctericidal cocktails. , Two prototype devices ha...of healthy skin (e.g. hands and feet) in hospitals...l threat; and another to shoot bacteria-killing ag...
(Date:11/25/2009)...irefighters, police officers and ambulance workers...de Center complex. They battled to save people fro...rs, tackled fires and evacuated as many people as ... 17,000 people. And making their jobs even harder ... workers and their relatives jammed mobile network...
(Date:11/25/2009)...versity assistant professors recently received fun... continue research beneficial to understanding the... Christopher Blackwood, assistant professor in the...ants to support two separate research projects. ,...omposer Communities and Functions from the Leaf to...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2FiLife Announces New Twitter Contest on Fixing the American Healthcare System 56561 1FiLife Announces New Twitter Contest on Fixing the American Healthcare System 56561 2Obesity Driving Americas Healthcare to a Tipping Point 56556 1Obesity Driving Americas Healthcare to a Tipping Point 56556 2Obesity Driving Americas Healthcare to a Tipping Point 56556 3Obesity Driving Americas Healthcare to a Tipping Point 56556 4Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP 1 Analog 13938 1Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP 1 Analog 13938 2Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP 1 Analog 13938 3
... extensive field campaign ever to investigate the ...ssion is poised to help scientists identify how ai...Arctic. , The recent decline of sea ice is one in...ronmental changes related to climate warming. NASA...re,s role in this climate-sensitive region with th...
... gas prices continue to soar to record highs, moto...cramp their pocketbooks. , Scientists at U.S. Dep... answering that call by working to chemically mani... of renewable fuels hydrogen gas. , We believe t...production of hydrogen by photosynthesis as a rene...
... obesity and diabetes be prevented before birth? ...B. Roberson Professor of Pediatrics and Professor ... Medicine, researching whether diseases that strik...duals while still in the womb, may enable physicia...ncy. , In a talk entitled Child Health Researc...
Other Biology News:NASA launches airborne study of arctic atmosphere, air pollution 2NASA launches airborne study of arctic atmosphere, air pollution 3Algae could one day be major hydrogen fuel source 2Leading pediatrician addresses the future of children's health 2
Fingerprinting II Dimensioning Techniques from Bio-Rad
Fingerprinting II Informatix Dimensioning Techniques from Bio-Rad
DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
Fingerprinting II Comparative Quantification and Polymorphism Analysis from Bio-Rad
Biology Products: